✦ LIBER ✦

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Scribed by Eberhardt, W.E.E.; Johnson, B.E.; Sun, Y.; Germonpré, P.; Saijo, N.; Zhou, C.; Wang, J.; Tada, H.; Kennedy, S.J.; Herbst, R.S.

Book ID: 122416628
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71714-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vandetanib plus docetaxel versus docetax

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

✍ Roy S Herbst; Yan Sun; Wilfried EE Eberhardt; Paul Germonpré; Nagahiro Saijo; Ca 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 327 KB

Docetaxel versus docetaxel plus gemcitab

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

✍ Georgoulias, Vassilis; Androulakis, Nikolaos; Kotsakis, Athanasios; Hatzidaki, D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Vandetanib Plus Pemetrexed for the Secon

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

✍ de Boer, R. H.; Arrieta, O.; Yang, C.-H.; Gottfried, M.; Chan, V.; Raats, J.; de 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 295 KB

9005 Vandetanib versus erlotinib in pati

9005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Goss, G.D.; Thongprasert, S.; Greco, F.A.; Thomas, M.; Tsai, C.M.; Sunpaweravong 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

9004 Vandetanib plus pemetrexed vs pemet

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Vansteenkiste, J.; Arrieta, O.; Gottfried, M.; Blackhall, F.H.; Raats, J.; Yang, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB